Announcement Overview
Shenzhen Hanyu Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Hanyu Pharmaceutical") and all members of the Board of Directors guarantee that the content of this announcement is true, accurate, and complete, without any false records, misleading statements, or significant omissions.
Special Risk Warning
As of the date of this announcement, the total amount of guarantees expected to be provided by Shenzhen Hanyu Pharmaceutical Co., Ltd. and its consolidated subsidiaries for the year 2026 has exceeded 100% of the Company's most recent audited net assets. Among these, the expected guarantee amount for entities with a debt ratio exceeding 70% is more than 50% of the Company's most recent audited net assets. All guarantees are between the Company, wholly-owned subsidiaries, and holding subsidiaries; investors are advised to pay attention to the related risks.
1. Overview of Guarantees
On January 28, 2026, the Company held the 12th meeting of the 6th Board of Directors, and on March 16, 2026, it held the second extraordinary general meeting of shareholders for 2026, which approved the proposal for applying for comprehensive credit and guarantee limits from financial institutions for 2026. The Company and its consolidated subsidiaries plan to apply for comprehensive credit facilities not exceeding RMB 1 billion for the year 2026, providing guarantees not exceeding RMB 1 billion in total. The expected guarantee amounts for entities with a debt ratio of 70% (inclusive) and above will not exceed RMB 700 million, while those below 70% will not exceed RMB 300 million, as detailed below:
| Project | Debt Ratio ≥ 70% | Debt Ratio < 70% |
|---|---|---|
| Company guarantees for subsidiaries and inter-subsidiary guarantees | Not exceeding 20 million | Not exceeding 280 million |
| Subsidiaries guarantee for the Company | Not exceeding 680 million | Not exceeding 20 million |
| Total | Not exceeding 700 million | Not exceeding 300 million |